Simeprevir

Overview

Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus ( HCV ) NS3/4A protease inhibitor with a K i of 0.36 nM. Simeprevir inhibits HCV replication with an EC 50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M pro ) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Infection | Products > Signaling Pathways > HCV | Products > Signaling Pathways > HCV Protease | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-10241
• CAS No.: 923604-59-5
• Molecular Formula: C38H47N5O7S2
• Molecular Weight: 749.94
• Purity: 98.79%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1.43 mg/mL (1.91 mM); Clear solution
• Availability: In-stock

Source

Original product source